490 ARSENAL WAY, WATERTOWN, MA
C4 Therapeutics Elects Andrew J. Hirsch and Others as Class III Directors
Reg. FD, Other Events
Departure of Chief Accounting Officer Mark Mossler at C4 Therapeutics
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Annual Report to Security Holders
By-Laws Amendment - C4 Therapeutics Designates Exclusive Forums
Expands Long-Term Partnership Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs), Investor Presentation
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Free Writing Prospectus